| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jerry D Clewell, Robert W Bake. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model". Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 8. issue 2. 2005-05-25. PMID:15804326. |
comments to the editor on "outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a markov model". |
2005-05-25 |
2023-08-12 |
Not clear |
| Joel M Boerth, Charles F Caley, John W Goeth. Interpreting serum risperidone concentrations. Pharmacotherapy. vol 25. issue 2. 2005-05-17. PMID:15767244. |
risperidone is an atypical antipsychotic commonly used for treatment of schizophrenia and other psychotic disorders. |
2005-05-17 |
2023-08-12 |
Not clear |
| John Lauriello, Joseph P McEvoy, Stephen Rodriguez, Cynthia A Bossie, Robert A Lasse. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia research. vol 72. issue 2-3. 2005-05-10. PMID:15560969. |
long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. |
2005-05-10 |
2023-08-12 |
Not clear |
| John Lauriello, Joseph P McEvoy, Stephen Rodriguez, Cynthia A Bossie, Robert A Lasse. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia research. vol 72. issue 2-3. 2005-05-10. PMID:15560969. |
long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia. |
2005-05-10 |
2023-08-12 |
Not clear |
| Mark Olfson, Thomas Uttaro, William H Carson, Eskinder Tafess. Male sexual dysfunction and quality of life in schizophrenia. The Journal of clinical psychiatry. vol 66. issue 3. 2005-04-28. PMID:15766299. |
to describe the prevalence and clinical correlates of sexual dysfunction in a sample of adult male outpatients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol, focusing on associations between sexual dysfunction and patient-perceived quality of life. |
2005-04-28 |
2023-08-12 |
Not clear |
| Deirdre M Mladsi, Amy L Grogg, William D Irish, Rebecca B Lopez, Kathleen Degen, Alan Swann, Christian T Nimsc. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Current medical research and opinion. vol 20. issue 12. 2005-04-19. PMID:15701206. |
pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. |
2005-04-19 |
2023-08-12 |
Not clear |
| J E Hovens, P J T Dries, C T M Melman, R J C Wapenaar, A J M Loone. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. Journal of psychopharmacology (Oxford, England). vol 19. issue 1. 2005-04-12. PMID:15671129. |
in this open study, consecutive adult patients presenting with an acute exacerbation of schizophrenia or other psychotic disorder were assigned to oral risperidone 2-6 mg/day (n = 48) or oral zuclopenthixol 20-50 mg/day (n = 27) for 7-14 days. |
2005-04-12 |
2023-08-12 |
Not clear |
| Mihai Nechifor, C Vaideanu, I Palamaru, C Borza, I Mindrec. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. Journal of the American College of Nutrition. vol 23. issue 5. 2005-04-08. PMID:15466963. |
the aim of the study was the investigation of plasma magnesium, calcium, copper and zinc and erythrocyte magnesium levels in patients with paranoid schizophrenia and the influence of the therapy with two antipsychotic drugs (haloperidol and risperidone) on these concentrations. |
2005-04-08 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Shih-Kuan Hsu, Yi-Ching Liu, Yue-Cune Chang, Chiung-Hsien Huang, Wen-Ho Chan. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. Journal of clinical psychopharmacology. vol 25. issue 1. 2005-04-08. PMID:15643094. |
risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia. |
2005-04-08 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Shih-Kuan Hsu, Yi-Ching Liu, Yue-Cune Chang, Chiung-Hsien Huang, Wen-Ho Chan. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. Journal of clinical psychopharmacology. vol 25. issue 1. 2005-04-08. PMID:15643094. |
one hundred twenty-three han chinese patients with acutely exacerbated schizophrenia were given risperidone monotherapy for up to 42 days. |
2005-04-08 |
2023-08-12 |
Not clear |
| Bruce L Lambert, Ken-Yu Chang, Eskinder Tafesse, William Carso. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. Journal of clinical psychopharmacology. vol 25. issue 1. 2005-04-08. PMID:15643095. |
to examine the risk of hyperlipidemia among people with schizophrenia exposed to new antipsychotics (clozapine, olanzapine, quetiapine, risperidone) compared with those exposed to older generation antipsychotics. |
2005-04-08 |
2023-08-12 |
Not clear |
| Seppo Kahkone. Trichotillomania in a schizophrenia patient. CNS spectrums. vol 7. issue 10. 2005-04-04. PMID:15034500. |
her schizophrenia was being treated with risperidone. |
2005-04-04 |
2023-08-12 |
Not clear |
| K Hansen, C François, M Toumi, C Lanço. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. The European journal of health economics : HEPAC : health economics in prevention and care. vol 3. issue 3. 2005-04-04. PMID:15609142. |
a pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. |
2005-04-04 |
2023-08-12 |
Not clear |
| . Case histories in drug discovery and design. Drug news & perspectives. vol 11. issue 1. 2005-03-30. PMID:15616642. |
the evolution of a new drug treatment for schizophrenia commenced with the observation that chlorpromazine possessed "neuroleptic" activity and progressed through studies with various dopamine and serotonin antagonists to ultimately lead to the discovery of risperidone. |
2005-03-30 |
2023-08-12 |
Not clear |
| Pierre Chue, Marielle Eerdekens, Ilse Augustyns, Bernard Lachaux, Peter Molcan, Lars Eriksson, H Pretorius, Anthony S Davi. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 15. issue 1. 2005-03-29. PMID:15572280. |
a double-blind study of long-acting injectable risperidone and oral risperidone tablets was conducted in 640 patients with schizophrenia. |
2005-03-29 |
2023-08-12 |
Not clear |
| Dieter Naber, Martin Lamber. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 8. 2005-03-07. PMID:15588748. |
in phase iii comparative clinical studies, aripiprazole 15-30 mg/day was at least as effective as haloperidol and risperidone in short term treatment of acute exacerbation of schizophrenia but superior to haloperidol in long term maintenance therapy. |
2005-03-07 |
2023-08-12 |
Not clear |
| Lynne E Rueter, Michael E Ballard, Kelly B Gallagher, Ana Maria Basso, Peter Curzon, Kathy L Kohlhaa. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology. vol 176. issue 3-4. 2005-03-01. PMID:15179541. |
chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. |
2005-03-01 |
2023-08-12 |
rat |
| Eduardo Pondé de Sena, Rogério Santos-Jesus, Angela Miranda-Scippa, Lucas de Castro Quarantini, Irismar Reis de Oliveir. Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 25. issue 4. 2005-03-01. PMID:15328547. |
relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. |
2005-03-01 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yue-Cune Chang, Chung-Ta Lu, Chiung-Hsien Huang, Wen-Ho Chan. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. The international journal of neuropsychopharmacology. vol 7. issue 4. 2005-02-24. PMID:15140279. |
risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia. |
2005-02-24 |
2023-08-12 |
Not clear |
| Hsien-Yuan Lane, Cheng-Chun Lee, Yue-Cune Chang, Chung-Ta Lu, Chiung-Hsien Huang, Wen-Ho Chan. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. The international journal of neuropsychopharmacology. vol 7. issue 4. 2005-02-24. PMID:15140279. |
a total of 123 han chinese patients with acutely exacerbated schizophrenia were given risperidone for up to 42 days. |
2005-02-24 |
2023-08-12 |
Not clear |